Encorafenib

恩考芬尼

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameEncorafenib
Drug Alias NameEncorafenibum恩拉非尼恩考芬尼恩可非尼Braftovi +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitors
TargetsSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHematologic Neoplasms +[6] 
Global Approved IndicationsColorectal NeoplasmsMelanoma
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2018/06/27
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesPierre Fabre LaboratoriesOno Pharma Korea Co LtdArray Biopharma +[11] 
Inactive CompaniesNational Cancer Institute
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeL01EC03
Related LinksWikipediaDrugBankKEGG